Germany’s BioNTech raises vaccine sales outlook to €12.4bn
Pfizer and BioNTech have also bumped up their production goals
10 May 2021 - 17:43
Mainz — BioNTech boosted its Covid-19 vaccine sales forecast to €12.4bn for 2021, issuing a new target for the shot it sells with Pfizer as countries increase orders to spur their inoculation campaigns.
The partners have contracted for about 1.8-billion doses in 2021 and started clinching deals for 2022 and beyond, the Mainz, Germany-based company said on Monday. BioNTech had previously predicted €9.8bn in 2021 revenue from the shot, its first marketed product...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.